The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.
The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.
The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present disclosure provides for an oncolytic virus comprising an exogenous nucleic acid encoding for a polypeptide that acts as a CD47-SIRP-alpha immune checkpoint inhibitor. Oncolytic viruses optionally comprise a mutation or deletion of the gene expressing IFN-gamma. Compositions described herein are further described for use in the treatment of cancer.
A61K 35/768 - Oncolytic viruses not provided for in groups
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present disclosure provides for nucleic acids encoding for a soluble PD-1 variant and IL-12. Further provided herein are nucleic acids encoding for a chemokine receptor. Additionally described herein are oncolytic viruses comprising the nucleic acids described herein. Oncolytic viruses optionally comprise a mutation or deletion of the gene expressing IFN-gamma. Compositions described herein are further described for use in the treatment of cancer.
The present disclosure provides for a nucleic acids encoding for a transforming growth factor inhibitor and IL-12. Further provided herein are nucleic acids encoding for chemokine receptor CXCR3. Additionally described herein are oncolytic viruses comprising the nucleic acids described herein. Compositions described herein are further described for use in the treatment of cancer.
The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.
The present disclosure provides for compositions comprising nucleic acids encoding for fusion proteins of the Tumor Necrosis Factor Super Family Ligands fused to oligomerization domains. Further provided are viral and non-viral vectors for delivery of such compositions. The present disclosure also provides for compositions comprising fusion proteins of the Tumor Necrosis Factor Super Family Ligands fused to oligomerization domains.
The present disclosure provides for compositions comprising nucleic acids encoding for fusion proteins of the Tumor Necrosis Factor Super Family Ligands fused to oligomerization domains. Further provided are viral and non-viral vectors for delivery of such compositions. The present disclosure also provides for compositions comprising fusion proteins of the Tumor Necrosis Factor Super Family Ligands fused to oligomerization domains.
The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I mid alternatively or additively upregulation of Major Histocompatibility Complex class IL Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of rising these compositions are also presented.
The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I mid alternatively or additively upregulation of Major Histocompatibility Complex class IL Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of rising these compositions are also presented.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biological products for medical and scientific research. Immunotherapeutics; biopharmaceutical preparations. Medical and scientific research in the fields of
immunotherapy, immunotherapeutics, biotechnology, and
biopharmaceuticals; immunotherapeutic and biopharmaceutical
drug development services.
16.
Producer Viruses for Generation of Retroviruses In Situ
This disclosure provides compositions comprising a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The viral compositions and methods provided herein can be utilized for the treatment of cancer.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biological products for medical and scientific research. Immunotherapeutics; biopharmaceutical preparations. Medical and scientific research in the fields of
immunotherapy, immunotherapeutics, biotechnology, and
biopharmaceuticals; immunotherapeutic and biopharmaceutical
drug development services.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of
immunotherapy, immunotherapeutics, biotechnology, and
biopharmaceuticals; immunotherapeutic and biopharmaceutical
drug development services.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of
immunotherapy, immunotherapeutics, biotechnology, and
biopharmaceuticals; immunotherapeutic and biopharmaceutical
drug development services.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of
immunotherapy, immunotherapeutics, biotechnology, and
biopharmaceuticals; immunotherapeutic and biopharmaceutical
drug development services.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Biological products for medical and scientific research
(2) Immunotherapeutics; biopharmaceutical preparations (1) Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Biological products for medical and scientific research.
(2) Immunotherapeutics; biopharmaceutical preparations. (1) Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services.
26.
ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICRO-ENVIRONMENT REMODELING
The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.
This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.
This disclosure provides a modified oncolytic poxvirus, such as a vaccinia virus, that can contain modifications in the viral genome that increases production of an extracellular enveloped form of the virus. The modified oncolytic poxvirus can be utilized as a vector for systemic delivery. Also provided are methods of using the modified oncolytic poxvirus.
Disclosed herein are methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms.
This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biological preparations for use in immunotherapy, namely, oncolytic vaccinia viruses; Pharmaceutical preparations for the treatment of oncological diseases and disorders, and complications associated therewith; Biopharmaceutical preparations for the treatment of treatment of cancer; Biopharmaceutical preparations for the treatment of oncological diseases and disorders, and complications associated therewith
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biological preparations for use in immunotherapy, namely, oncolytic vaccinia viruses; Pharmaceutical preparations for the treatment of oncological diseases and disorders, and complications associated therewith; Biopharmaceutical preparations for the treatment of cancer; Biopharmaceutical preparations for the treatment of oncological diseases and disorders, and complications associated therewith
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of immunotherapy, immunotherapeutics, biotechnology, and biopharmaceuticals; immunotherapeutic and biopharmaceutical drug development services
Provided herein are methods of manufacturing viruses. Also provided herein are bioreactors comprising virus-infected host cells comprising viruses. In some aspects, the present disclosure relates to production of recombinant oncolytic viruses, e.g., recombinant vaccinia viruses.
This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.
This disclosure provides compositions comprising a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The viral compositions and methods provided herein can be utilized for the treatment of cancer. One embodiment provides a virus that produces from its genome a non-replicating retrovirus, wherein the virus is an oncolytic virus.
This disclosure provides a modified oncolytic poxvirus, such as a vaccinia virus, that can contain modifications in the viral genome that increases production of an extracellular enveloped form of the virus. The modified oncolytic poxvirus can be utilized as a vector for systemic delivery. Also provided are methods of using the modified oncolytic poxvirus.
This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.
Disclosed herein are methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms. Methods provided herein include methods of inducing or enhancing an immune response in vivo in a subject.
C12N 1/11 - ProtozoaCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
Provided herein are methods of manufacturing viruses. Also provided herein are bioreactors comprising virus-infected host cells comprising viruses. In some aspects, the present disclosure relates to production of recombinant oncolytic viruses, e.g., recombinant vaccinia viruses.
This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.
